Clinical Characteristics and Disease Burden of Patients with Moderate-to-Severe Generalized Pustular Psoriasis Flares in Taiwan
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Clinical Characteristics and Disease Burden of Patients with Moderate-to-Severe Generalized Pustular Psoriasis Flares in Taiwan ; volume:14 ; number:8 ; day:30 ; month:7 ; year:2024 ; pages:2261-2275 ; date:8.2024
Dermatology and therapy ; 14, Heft 8 (30.7.2024), 2261-2275, 8.2024
- Creator
-
Lu, Chun-Wei
Tseng, Chien-Yu
Wang, Chuang-Wei
Lin, Shang-Hung
Chen, Chun-Bing
Hui, Rosaline Chung-Yee
Chi, Ching-Chi
Huang, Yu-Huei
Lee, Chih-Hung
Lin, Fang-Ju
Chung, Wen-Hung
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-024-01228-7
- URN
-
urn:nbn:de:101:1-2411052107395.375307992572
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lu, Chun-Wei
- Tseng, Chien-Yu
- Wang, Chuang-Wei
- Lin, Shang-Hung
- Chen, Chun-Bing
- Hui, Rosaline Chung-Yee
- Chi, Ching-Chi
- Huang, Yu-Huei
- Lee, Chih-Hung
- Lin, Fang-Ju
- Chung, Wen-Hung
- SpringerLink (Online service)
Other Objects (12)
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations